NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Avistone Pharmaceuticals

Avistone Pharmaceuticals

Private
BeijingHealthcare & Life Scienceshttps://www.avistonebio.com/

Last Round

Series B

Jan 4, 2024

Total Funding Raised

$340M

Company Overview

Avistone Pharmaceuticals is a biotechnology company that develops innovative drugs for tumor treatment and precision oncology therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

precision oncologytargeted therapykinase inhibitorcancer drugoncology biotechnon-small cell lung cancerNSCLCGBMglioblastomabiopharmaceuticalsmall-molecule drugdrug developmentEGFR inhibitorMET inhibitorclinical trial

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Avistone Pharmaceuticals Comparables

Compare Avistone Pharmaceuticals with similar companies based on industry and business-model similarity.

Avistone Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
HaiHe Biopharma
86%
Apollomics
84%
HUTCHMED (China) Limited
83%

Avistone Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 4, 2024
Series ADec 8, 2021

Avistone Pharmaceuticals Investors

Notable investors and investment history

Avistone Pharmaceuticals investors
InvestorRounds
Cathay CapitalSeries B
IDG CapitalSeries B
Yanchuang CapitalSeries B
SDIC Unity CapitalSeries B
IDG CapitalSeries B
Bain Capital, LPSeries A, Series B
Primavera Capital GroupSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2025

    Presented results at the ASCO Annual Meeting 2025.

  • Jun 1, 2025

    Encouraging results for combination therapy in lung cancer presented at ASCO.

Avistone Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Avistone Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Avistone Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Employee Range8
Year Founded2018
Last FundingJan 4, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.